Generic Name and Formulations:
Ceftaroline fosamil 400mg/vial, 600mg/vial; pwd for IV infusion after reconstitution.
- Ceftaroline Fosamil Effective in Treating ABSSSI in Obese Patients, Diabetics
- Ceftaroline Fosamil Highly Effective for Skin Infections in Patients with Diabetes or PVD
- Teflaro approved for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection
Indications for TEFLARO:
Susceptible bacterial community-acquired pneumonia and acute skin and skin structure infections.
≥18yrs: Give by IV infusion over 1hr. Treat skin and skin structure for 5–14 days; treat pneumonia for 5–7days. CrCl >50mL/min: 600mg every 12hrs. Renal impairment (CrCl >30–≤50mL/min): 400mg every 12hrs; (CrCl ≥15–≤30mL/min): 300mg every 12hrs; ESRD (including hemodialysis): 200mg every 12hrs (dose after dialysis on dialysis days).
<18yrs: not recommended.
Penicillin or other allergy. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
GI upset, rash, (+) Coombs test (evaluate for hemolytic anemia if occurs), pseudomembranous colitis, superinfection.